# Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

> **NCT01928199** · PHASE4 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 61 (actual)

## Conditions studied

- Posttransplant Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01928199
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2020-06
- **Final completion:** 2020-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928199, "Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01928199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*